Optic Nerve and Retinal Functions With Bevacizumab

Electrophysiological Assessment of Optic Nerve and Retinal Functions Following Intravitreal Injection of Bevacizumab (Avastin).

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01361828

Enrollment

Registered

2011-05-27

Start date

2010-01-31

Completion date

2010-07-31

Last updated

2011-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Choroidal Neovascular Membrane

Keywords

Bevacizumab, VEP, ERG, Optic nerve and retinal functions following intravitreal bevacizumab

Brief summary

The purpose of this study is to investigate the possible affection of optic nerve and retinal functions following intravitreal bevacizumab injection in human eyes.

Detailed description

To evaluate the retinal and optic nerve functions of bevacizumab when injected intravitreal in human eyes using electrophysiological tests; Electroretinogram (ERG) and Visual Evoked Potentials (VEP). Forty five eyes of 45 patients with choroidal neovascular membrane (CNV) who were prepared for intravitreal injections of 1.25mg bevacizumab underwent baseline ERG and VEP in both eyes before, and at 1 and 4 weeks after the intravitreal injections.

Interventions

PROCEDUREElectrophysiology

Visual Evoked Potential and Elctroretinogram

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

24 Years to 62 Years

Healthy volunteers

Inclusion criteria

* CNV

Exclusion criteria

* Previous Intravitreal Injections

Design outcomes

Primary

Measure	Time frame	Description
Visual Evoked Potential and Electroretinogram	4 weeks	VEP and ERG baseline and at 1 and 4 weeks post intravitreal injection of bevacizumab.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026